ArticleOPEN ACCESS

Maintenance therapy for AML: Are we there yet?

Blood
DOI: 10.1182/blood-2019-02-897579
7Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In this issue of Blood, Huls et al present positive results from a randomized study (HOVON97) showing that disease-free survival (DFS) in older patients with acute myeloid leukemia (AML) was improved by azacitidine compared with postremission observation.

Cite

CITATION STYLE

APA

Wei, A. H. (2019, March 28). Maintenance therapy for AML: Are we there yet? Blood. American Society of Hematology. https://doi.org/10.1182/blood-2019-02-897579

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free